News

Pharmaceuticals & Health News

Latest Pharmaceuticals & Health News

AstraZeneca share price: Group’s Tagrisso approved in China

AstraZeneca’s (LON:AZN) oncology treatment Tagrisso has been granted approval in China, the Anglo-Swedish drugmaker has said. The news marks a boost for the Anglo-Swedish pharmco which has bet on oncology as one of its key therapy areas to propel growth...

AstraZeneca share price rises amid drug trials results

AstraZeneca’s (LON:AZN) share price has advanced in London this morning as the company posted upbeat trial results for its cardiovascular treatments Brilinta and Farxiga. The results mark a boost for the blue-chip drugmaker which is counting on several key treatment...

GSK share price surges as pharmco lifts earnings guidance

GlaxoSmithKline’s (LON:GSK) share price has climbed higher in London in afternoon trade as the company lifted its full-year earnings guidance. The blue-chip pharmco further unveiled the appointment of Jonathan Symonds as its new chairman confirming reports from earlier this month....

AstraZeneca share price: Investors eye Q2 update

AstraZeneca’s (LON:AZN) new oncology treatments will be in focus as the Anglo-Swedish drugmaker updates investors on its half-year performance this week. The statement will come after the company said in April that its product sales had grown 10 percent in...

GSK share price: Pharmco looks to sell some consumer brands

GlaxoSmithKline (LON:GSK) has kicked off the sale of some consumer health brands as it seeks to raise about £1 billion, Reuters has reported. The news comes as the blue-chip drugmaker prepares to press ahead with a spinoff of its consumer...

AstraZeneca share price rises amid Lynparza approval

AstraZeneca’s share price (LON:AZN) as climbed higher in London in today’s session as the company’s drug Lynparza was approved in Europe as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The news marks a boost for the...

GSK share price subdued as Morgan Stanley resumes coverage

GSK’s share price (LON:GSK) has fallen marginally into the red in London in today’s session as Morgan Stanley resumed coverage of the blue-chip drugmaker with an ‘underweight’ rating. Proactive Investors quoted the broker as commenting that the company was ‘very...

Smith & Nephew share price: Group snaps up Atracsys

Smith & Nephew (LON:SN) has inked a deal to buy Atracsys, a Switzerland-based provider of optical tracking technology, the blue-chip company has said. The news comes after the London-listed artificial hips and knees maker recently wrapped up the acquisition of...

GSK share price up as FDA okays self-administration of asthma therapy

Shares in GlaxoSmithKline (LON:GSK) have climbed higher in London in today’s session as US regulators approved two new ways of administering a treatment for severe asthma. The update follows the blue-chip group’s recent first-quarter results which revealed a rise in...

AstraZeneca share price down despite upbeat trial results

AstraZeneca’s share price (LON:AZN) has fallen into the red this morning even as the blue-chip group posted upbeat results from a trial evaluating its oncology treatment Lynparza. The update follows the Anglo-Swedish group’s recent first-quarter results which saw the company...

Smith & Nephew share price: Group wraps up Brainlab deal

Smith & Nephew (LON:SN) has wrapped up the acquisition of the Brainlab orthopaedic joint reconstruction business, the blue-chip company has said. The move came after the artificial hips and knees maker recently inked a deal to buy NASDAQ-listed Osiris Therapeutics...

GSK share price: Pharmco still struggles to turn profits into cash

Hargreaves Lansdown reckons that while GlaxoSmithKline (LON:GSK) has delivered profits ahead of expectations, it is still struggling to turn them into cash, Citywire reports. The comments came after the blue-chip drugmaker posted a rise in sales and earnings earlier this...

GSK share price volatile as group posts rise in Q1 sales

Shares in GlaxoSmithKline (LON:GSK) have retreated in London this afternoon following an initial jump as the blue-chip drugmaker posted a rise in sales and earnings, having benefitted from strong demand for its vaccines and HIV treatments. The company, however, continues...

AstraZeneca share price: Deutsche Bank remains bullish on pharmco

Deutsche Bank continues to see AstraZeneca (LON:AZN) as a ‘buy,’ pointing to the pharmco’s ‘strong start’ to the year, Sharecast reports. The comments came after the Anglo-Swedish drugmaker updated investors on its first-quarter performance last week, posting a rise in...

AstraZeneca share price subdued despite rise in Q1 sales

Shares in AstraZeneca (LON:AZN) have slipped into the red in London in today’s session, even as the blue-chip drugmaker posted a rise in sales for the first three months of the year. The Anglo-Swedish pharmco disclosed that it had benefitted...

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.